Previous 10 | Next 10 |
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire - Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on formulary approvals at t...
2024-03-25 13:31:48 ET More on biolinerx Seeking Alpha’s Quant Rating on biolinerx Historical earnings data for biolinerx Financial information for biolinerx Read the full article on Seeking Alpha For further details see: biolinerx Q4 2023 ...
2024-03-24 08:01:00 ET Westport Fuel Systems ( WPRT ) is set to report its Q4 earnings on Monday after the closing bell. The stock, which has dropped about 24% over a 12-month period, has received a Buy rating from Wall Street analysts, while Seeking Alpha's Quant Rating system has ...
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 PR Newswire - Management to Hold Conference Call at 08:30 a.m. EDT - TEL AVIV, Israel , March 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial sta...
2024-03-06 09:10:00 ET March 6, 2024 Investorideas.com , a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Biotech Inc. ( NASDAQ: ONCY ) (TSX: ONC ), a clinical-stage i...
2024-03-06 08:40:19 ET Vancouver, Kelowna and Delta, British Columbia – March 6, 2024 – Investorideas.com , a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Bi...
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production PR Newswire - New patent, when issued, will be valid until December 2041 - - Add...
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) PR Newswire - Conducted in Collaboration with Columbia University , the CheMo4METPANC Phase 2 trial is the first large, ...
2024-02-25 14:12:12 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In almost every situation, investors should stay away from penny stocks . They’re extremely speculative and they tend to facilitate delusions of grandeur. To be sure, there’s ...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Ltd. Company Name:
BLRX Stock Symbol:
NASDAQ Market:
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 PR Newswire - Presentation Today, Monday, May 6, 2024 in Atlanta , Geo...
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting PR Newswire TEL AVIV, Israel , April 17, 2024 /PRNewswire/ --...
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement PR Newswire - Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sic...